Tumor infiltrated CD8+ T cells, the main player of anti-tumor immunity and producers of interferon gamma (IFN-γ), is highly relevant for predicting the therapeutic response to anti-PD-1/PD-L1 therapy [8, 9]. The gene discussed is IFNG; the disease is neoplasm.